Literature DB >> 29976628

Potential of Protein-based Anti-metastatic Therapy with Serpins and Inter α-Trypsin Inhibitors.

Ulrich H Weidle1, Fabian Birzele2, Georg Tiefenthaler3.   

Abstract

In this review we summarize the principles of anti-metastatic therapy with selected serpin family proteins, such as pigment epithelial-derived factor (PEDF) and maspin, as well as inter α-trypsin inhibitor (IαIs) light chains (bikunin) and heavy chains (ITIHs). Case-by-case, antimetastatic activity may be dependent or independent of the protease-inhibitory activity of the corresponding proteins. We discuss the incidence of target deregulation in different tumor entities, mechanisms of deregulation, context-dependent functional issues as well as in vitro and in vivo target validation studies with transfected tumor cells or recombinant protein as anti-metastatic agents. Finally, we comment on possible clinical evaluation of these proteins in adjuvant therapy. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Adjuvant anti-metastatic therapy; bikunin; in vitro and in vivo target validation; inter α-trypsin inhibitors; maspin; pigment-epithelial derived factor; protein substitution therapy; review

Mesh:

Substances:

Year:  2018        PMID: 29976628      PMCID: PMC6070713          DOI: 10.21873/cgp.20081

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  125 in total

Review 1.  Mechanisms governing metastatic dormancy and reactivation.

Authors:  Filippo G Giancotti
Journal:  Cell       Date:  2013-11-07       Impact factor: 41.582

Review 2.  Serpin structure, function and dysfunction.

Authors:  J A Huntington
Journal:  J Thromb Haemost       Date:  2011-07       Impact factor: 5.824

Review 3.  The intracellular serpin family.

Authors:  R Korpula-Mastalerz; A Dubin
Journal:  Acta Biochim Pol       Date:  1996       Impact factor: 2.149

4.  Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor.

Authors:  Olga V Volpert; Tetiana Zaichuk; Wei Zhou; Frank Reiher; Thomas A Ferguson; P Michael Stuart; Mohammad Amin; Noel P Bouck
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

5.  Nuclear localization of maspin is essential for its inhibition of tumor growth and metastasis.

Authors:  Brigitte Goulet; Wendy Kennette; Amber Ablack; Carl O Postenka; M Nicole Hague; Joe S Mymryk; Alan B Tuck; Vincent Giguère; Ann F Chambers; John D Lewis
Journal:  Lab Invest       Date:  2011-04-18       Impact factor: 5.662

6.  Inter-α-trypsin inhibitor heavy chain 5 (ITIH5) is overexpressed in inflammatory skin diseases and affects epidermal morphology in constitutive knockout mice and murine 3D skin models.

Authors:  Sebastian Huth; Ruth Heise; Claudia S Vetter-Kauczok; Claudia Skazik; Yvonne Marquardt; Katharina Czaja; Ruth Knüchel; Hans F Merk; Edgar Dahl; Jens M Baron
Journal:  Exp Dermatol       Date:  2015-04-17       Impact factor: 3.960

7.  Inhibition of orthotopic osteosarcoma growth and metastasis by multitargeted antitumor activities of pigment epithelium-derived factor.

Authors:  Eugene T H Ek; Crispin R Dass; Karla G Contreras; Peter F M Choong
Journal:  Clin Exp Metastasis       Date:  2007-04-18       Impact factor: 5.150

8.  Pigment epithelium-derived factor: neurotrophic activity and identification as a member of the serine protease inhibitor gene family.

Authors:  F R Steele; G J Chader; L V Johnson; J Tombran-Tink
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-15       Impact factor: 11.205

9.  γ-Secretase and presenilin mediate cleavage and phosphorylation of vascular endothelial growth factor receptor-1.

Authors:  Jun Cai; Zhijuan Chen; Qing Ruan; Song Han; Li Liu; Xiaoping Qi; Sanford L Boye; William W Hauswirth; Maria B Grant; Michael E Boulton
Journal:  J Biol Chem       Date:  2011-10-20       Impact factor: 5.157

10.  Anti-metastatic therapy by urinary trypsin inhibitor in combination with an anti-cancer agent.

Authors:  H Kobayashi; H Shinohara; J Gotoh; M Fujie; S Fujishiro; T Terao
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

View more
  6 in total

1.  Revelation of Proteomic Indicators for Colorectal Cancer in Initial Stages of Development.

Authors:  Arthur T Kopylov; Alexander A Stepanov; Kristina A Malsagova; Deepesh Soni; Nikolay E Kushlinsky; Dmitry V Enikeev; Natalia V Potoldykova; Andrey V Lisitsa; Anna L Kaysheva
Journal:  Molecules       Date:  2020-01-31       Impact factor: 4.411

2.  Deiminated proteins in extracellular vesicles and serum of llama (Lama glama)-Novel insights into camelid immunity.

Authors:  Michael F Criscitiello; Igor Kraev; Sigrun Lange
Journal:  Mol Immunol       Date:  2019-11-13       Impact factor: 4.407

3.  ITIH5-Derived Polypeptides Covering the VIT Domain Suppress the Growth of Human Cancer Cells In Vitro.

Authors:  Michael Rose; Sebastian Huth; Marc Wiesehöfer; Josef Ehling; Corinna Henkel; Julia Steitz; Twan Lammers; Jennifer Kistermann; Oliver Klaas; Maximilian Koch; Sandra Rushrush; Ruth Knüchel; Edgar Dahl
Journal:  Cancers (Basel)       Date:  2022-01-19       Impact factor: 6.639

4.  Maspin, Syndecan-1, and Ki-67 in the Odontogenic Keratocyst: An Immunohistochemical Analysis.

Authors:  Huda M Hammad; Omar M Nagrash; Rima A Safadi
Journal:  Int J Dent       Date:  2020-07-14

5.  Alpha1-antitrypsin protects lung cancer cells from staurosporine-induced apoptosis: the role of bacterial lipopolysaccharide.

Authors:  Natalie Schwarz; Srinu Tumpara; Sabine Wrenger; Evrim Ercetin; Jürg Hamacher; Tobias Welte; Sabina Janciauskiene
Journal:  Sci Rep       Date:  2020-06-12       Impact factor: 4.379

6.  Quantitative proteomic analysis of GnRH agonist treated GBM cell line LN229 revealed regulatory proteins inhibiting cancer cell proliferation.

Authors:  Priyanka H Tripathi; Javed Akhtar; Jyoti Arora; Ravindra Kumar Saran; Neetu Mishra; Ravindra Varma Polisetty; Ravi Sirdeshmukh; Poonam Gautam
Journal:  BMC Cancer       Date:  2022-02-02       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.